Low Serum Testosterone Level Predicts Worse Response to Endocrine Therapy in Japanese Patients with Metastatic Prostate Cancer
| Autor: | Osamu Nagakawa, Hideki Fuse, Yuzo Furuya, Tetsuo Nozaki |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
Oncology medicine.medical_specialty Neoplasms Hormone-Dependent Antineoplastic Agents Hormonal Chlormadinone Acetate medicine.drug_class Endocrinology Diabetes and Metabolism medicine.medical_treatment Bone Neoplasms Disease Statistics Nonparametric Gonadotropin-Releasing Hormone Tosyl Compounds Prostate cancer Endocrinology Japan Antigen Predictive Value of Tests Internal medicine Nitriles Humans Medicine Anilides Testosterone Diethylstilbestrol Aged Aged 80 and over business.industry Prostatic Neoplasms Middle Aged Prostate-Specific Antigen medicine.disease Androgen Flutamide Prostate-specific antigen Predictive value of tests Disease Progression Hormone therapy business |
| Zdroj: | Endocrine Journal. 49:85-90 |
| ISSN: | 1348-4540 0918-8959 |
| Popis: | Patients with prostate cancer generally respond to androgen withdrawal therapy, but progression to androgen-independence is frequently observed later. To examine whether pretreatment serum androgen status could predict disease progression in metastatic prostate cancer, pretreatment serum testosterone, histological grade, extent of bony metastasis, serum prostate-specific antigen (PSA) response to hormone therapy, and prognosis of the 40 patients with untreated metastatic prostate cancer who received endocrine therapy were evaluated. Although there were no differences in age, pretreatment PSA level, extent of bony disease and histological grade between patients with normal testosterone and those with low testosterone, PSA response after endocrine therapy was better in normal testosterone group. There was a significantly longer interval to disease progression in patients with normal testosterone than in those with low testosterone. The patients with metastatic prostate cancer with low serum testosterone were in the high risk group of worse response to endocrine therapy. Additional therapy might be considered in those patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|